Skip to content

Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE

Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00147979
Enrollment
596
Registered
2005-09-07
Start date
2004-04-30
Completion date
2013-08-31
Last updated
2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Diseases

Brief summary

Comparison of two kinds of protheses for bridging of the femoropoplitea and/or femorotibiale: PTFE with or without bounded heparin

Detailed description

Comparison of two kinds of protheses for bridging of the femoropoplitea and/or femorotibiale: PTFE with or without bounded heparin. Evaluation of this comparison by clinical systems: ankle-arm index, duplex echo, follow-up of 2 years

Interventions

DEVICEBridging by PTFE with bounded heparin

Bridging by PTFE with bounded heparin

DEVICEBridging by PTFE without bounded heparin

Bridging by PTFE without bounded heparin

Sponsors

JOTEC Company
CollaboratorOTHER
University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Peripheral Vascular Diseases with complaints of invalidating claudication, rest pain, ucera or gangrene * Patients with damage of the arteria femoralis superficialis or poplitea, longer than 6 cm * Reasonable outflow arteria * Informed consent * Patient able to take part in all follow-up examinations

Exclusion criteria

* Acute ischemia of the leg * Patients with a ipsilateral inflow stenosis of more than 70% which can not be corrected before or during the surgery * \< 18 years * Pregnancy * Recent heart attack (\< 1 month) * Life expectancy less than 12 months * Known allergy to heparin * Known contrast allergy * Known bleeding or coagulation disorder

Design outcomes

Primary

MeasureTime frame
Primary patency after 2 yearsafter 2 years

Secondary

MeasureTime frame
Secondary patencyafter 2 years
Limb salvageafter 2 years
Mortalityafter 2 years
Re-interventionafter 2 years

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026